Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Oxford Nanopore Technologies's Debt-to-EBITDA or its related term are showing as below:
OXFYY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.68 Med: -0.41 Max: -0.17
Current: -0.48
During the past 8 years, the highest Debt-to-EBITDA Ratio of Oxford Nanopore Technologies was -0.17. The lowest was -0.68. And the median was -0.41.
OXFYY's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs OXFYY: -0.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Oxford Nanopore Technologies Debt-to-EBITDA Related Terms
Oxford Nanopore Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXFYY vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Oxford Nanopore Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford Nanopore Technologies Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oxford Nanopore Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Oxford Nanopore Technologies (OXFYY) has a Debt-to-EBITDA of -0.49 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Oxford Nanopore Technologies. According to the industry distribution chart, Oxford Nanopore Technologies ranks #999999 out of 291 companies in the Biotechnology industry.
Is Oxford Nanopore Technologies' Debt-to-EBITDA too high?
Oxford Nanopore Technologies' current Debt-to-EBITDA is -0.49. Based on the distribution chart, Oxford Nanopore Technologies ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford Nanopore Technologies has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxford Nanopore Technologies' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford Nanopore Technologies ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Oxford Nanopore Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Oxford Nanopore Technologies. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford Nanopore Technologies's current Debt-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford Nanopore Technologies stock overvalued right now?
Based on GuruFocus' analysis, Oxford Nanopore Technologies (OXFYY) is currently considered Significantly Undervalued. The stock's GF Value™ is $10.34, compared to a current price of $6.50 — trading 37.1% below its estimated fair value. The current Debt-to-EBITDA is -0.49. Oxford Nanopore Technologies' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Oxford Nanopore Technologies (OXFYY), the current Debt-to-EBITDA is -0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford Nanopore Technologies (OXFYY) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford Nanopore Technologies stock appears to be undervalued.
The current stock price of $6.50 is trading 37.1% below its estimated GF Value™ of $10.34.
GuruFocus considers Oxford Nanopore Technologies to be Significantly Undervalued.
Key valuation signals for OXFYY:
Debt-to-EBITDA: -0.49
GF Value™: $10.34 vs. price of $6.50 (37.1% below fair value)
No single metric tells the full story. See the OXFYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC.
50GF Score
Get the complete analysis for OXFYY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXFYY has been successfully added to your 
